We previously demonstrated that concomitant targeting of HGF and MET allows optimal blockage of the ligand/receptor axis, strongly reducing the metastatic spreading of pancreatic cancer cells [16,17]. The gene discussed is HGF; the disease is familial pancreatic carcinoma.